This site is best viewed with a modern browser. You appear to be using an old version of Internet Explorer.

Developing a vaccine to prevent RSV, a cause of serious respiratory infections in infants

Trial categories: Vaccines

Sponsoring organisation: Janssen Vaccines & Prevention B.V

A Randomized, Double-blind, Phase 1/2a Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.preF in Adults 18 to 50 Years of Age and RSV-Seropositive Toddlers 12 to 24 Months of Age

You are invited to take part in a study to investigate a new vaccine against Respiratory Syncytial Virus (RSV), a highly infectious respiratory virus that infects the lungs and breathing passages. The study is being run by the Oxford Vaccine Group at the University of Oxford.

If you are 18 to 50 yrs old and are in good health then you may be eligible to take part in this study. We will provide reimbursement for your time, inconvenience and travel. The total study participation time is 30 weeks.

"What does the study involve?" "What will I have to do?" These are important questions.

For further information, please visit:

http://trials.ovg.ox.ac.uk/trials/prevent-rsv

or contact us on:

Tel: 01865 611400
Email: info@ovg.ox.ac.uk

Back to list of trials